期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 87, 期 1, 页码 90-100出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2012.12.003
关键词
Bleomycin; Hodgkin's Lymphoma; Testicular germ-cell tumour; Lung injury; Therapeutics; Safe clinical use; Toxicity
资金
- Hellenic Society of Haematology Foundation
Bleomycin is a key component of curative chemotherapy regimens employed in the treatment of curable cancers, such as Hodgkin lymphoma (HL) and testicular germ-cell tumours (GCT), yet its use may cause bleomycin-induced lung injury (BILI), which is associated with significant morbidity and a mortality rate of 1-3%. Diagnosis of BILI is one of exclusion and physicians involved in the care of HL and GCT patients should be alerted. Pharmacogenomic studies could contribute towards the identification of molecular predictors of bleomycin toxicity on the aim to optimize individual use of bleomycin. We review all existing data on bleomycin's most recent integrated chemical biology, molecular pharmacology and mature clinical data and provide guidelines for its safe clinical use. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据